1.61 Postpublication Metrics of RCTs, PCP Appointment Time, Bortezomib, & Dr. Christopher Booth

Plenary Session

English - May 15, 2019 23:13 - 2 hours - 155 MB - ★★★★★ - 732 ratings
Science Health & Fitness Medicine medicine oncology health policy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung

Next Episode: 1.62 Rates of Cancer Screening, BILCAP Outcry, Waterfall Plots and Response Rate, & Dr. Jeff Sharman

This week we cover three papers -- "Postpublication Metrics of Randomized Clinical Trials With and Without Null Findings" by Murray et al. in JAMA, "Association of Primary Care Clinic Appointment Time With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening" by Hsiang et al. in JAMA Network Open, and "Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers" by Drilon et al. in Molecular Case Studies. We end with an interview with Dr. Christopher Booth of Queens University in Kingston, Ontario, conducted in the Plenary Session Mobile Command Unit.

Postpublication Metrics: doi.org/10.1001/jama.2019.2994
PCP Appointment Time: doi.org/10.1001/jamanetworkopen.2019.3403
Exceptional Responders: doi.org/10.1101/mcs.a003665

Back us on Patreon! www.patreon.com/plenarysession